ピーナッツアレルギー治療薬市場:パイプライン分析・治験・特許・指定・協力・動向

【英語タイトル】Peanut Allergy Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

P&S Market Researchが出版した調査資料(PSM804034)・商品コード:PSM804034
・発行会社(調査会社):P&S Market Research
・発行日:2018年3月
・ページ数:88
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD1,850 ⇒換算¥209,050見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Peanut Allergy Therapeutics Pipeline in 2018
Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately 19 drug candidates in different stages of development.

Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of peanut allergy are being developed to be administered by the oral route which is convenient to take, and has been considered as non-invasive, and is often a safer route that requires no special training to be given to the patients.

Peanut Allergy Therapeutics Pipeline growth characterized by Various Technological Advancements

It has been observed that most of the companies are developing drug candidates by using advanced technologies and the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, BioLingus Inc. is utilizing its technology, BioLingus technology, which is a micro-encapsulation process, that delivers macro molecules such as peptides and proteins and is particularly effective for sublingual immunotherapy. With this technology, it has been observed in the Pre-Clinical models that sublingual IL-2 is found efficacious in 500th times lower amount than the investigational sublingual IL-2 therapy for the treatment of peanut allergy.

Some of the key players involved in the development of peanut allergy therapeutics include Aimmune Therapeutics Inc., DBV Technologies S.A., and AnaptysBio Inc.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.2 Sign & Symptoms

4.3 Pathophysiology

4.4 Epidemiology

4.5 Diagnosis

4.6 Prevention and Treatment

4.7 Key Drivers

4.7.1 Rise in the Number of Patent Approvals

4.7.2 Driver 2

4.8 Key Barriers

4.8.1 Risks Involved in the Development of Drug Candidates

4.9 Peanut Allergy Therapeutics Pipeline Analysis

4.9.1 Pipeline Analysis by Phase

4.9.2 Pipeline Analysis by Molecule Type

4.9.3 Pipeline Analysis by Route of Administration

4.9.4 Pipeline Analysis by Company

Chapter 5. Peanut allergy Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 AR-101

5.1.1.1 Clinical trial

5.1.1.2 Clinical results

5.1.1.3 Designation

5.1.1.4 Patent

5.1.2 XXXX

5.1.2.1 Clinical trial

5.1.2.2 Strategic development

5.1.2.3 Technology

5.2 Phase II

5.2.1 XXXX

5.2.1.1 Clinical trial

5.2.1.2 Strategic development

5.2.1.3 Patent

5.2.1.4 Technology

5.3 Phase I

5.3.1 HAL-MPE1

5.3.1.1 Clinical trial

5.3.1.2 Clinical result

5.3.2 XXXX

5.3.2.1 Strategic development

5.3.3 XXXX

5.3.3.1 Clinical trials

5.3.3.2 Strategic development

5.3.3.3 Technology

5.3.3.4 Designation

5.3.3.5 Patent

5.3.3.6 Grant

5.3.4 XXXX

5.3.5 XXXX

5.3.5.1 Strategic development

5.3.5.2 Technology

5.3.6 XXXX

5.3.6.1 Technology

5.4 Pre-Clinical

5.4.1 Low dose sublingual IL-2 (Project B7 (SLIT))

5.4.1.1 Technology

5.4.2 XXXX

5.4.3 XXXX

5.4.3.1 Pre-Clinical results

5.4.3.2 Clinical trials

5.4.3.3 Technology

5.4.4 XXXX

5.4.5 XXXX

5.4.5.1 Technology

5.4.6 XXXX

5.4.6.1 Pre-Clinical studies

5.4.7 XXXX

5.5 Discovery

5.5.1 VTC-064

5.5.1.1 Strategic development

5.5.2 XXXX

5.5.2.1 Strategic development

5.5.2.2 Technology

5.5.3 XXXX

5.5.3.1 Technology

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Peanut Allergy Therapeutics Pipeline

7.2 SWOT Analysis of Peanut Allergy Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 AnaptysBio Inc.

8.1.1 Business Overview

8.1.2 Product and Service Offerings

8.2 Aimmune Therapeutics Inc.

8.2.1 Business Overview

8.2.2 Product and Service Offerings

8.3 Company 3

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 Company 4

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 Company 5

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 Company 6

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 Company 7

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 Company 8

8.8.1 Business Overview

8.8.2 Product and Service Offerings

8.9 Company 9

8.9.1 Business Overview

8.9.2 Product and Service Offerings

8.10 Company 10

8.10.1 Business Overview

8.10.2 Product Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS OF PEANUT ALLERGY THERAPEUTICS, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF AR-101

TABLE 3 CLINICAL TRIALS OF AR-101

TABLE 4 DESCRIPTION OF XXXX

TABLE 5 CLINICAL TRIALS OF XXXX

TABLE 6 DESCRIPTION OF XXXX

TABLE 7 CLINICAL TRIALS OF XXXX

TABLE 8 DESCRIPTION OF HAL-MPE1

TABLE 9 CLINICAL TRIALS OF HAL-MPE1

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 DESCRIPTION OF XXXX

TABLE 12 CLINICAL TRIALS OF XXXX

TABLE 13 DESCRIPTION OF XXXX

TABLE 14 DESCRIPTION OF XXXX

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 DESCRIPTION OF LOW DOSE SUBLINGUAL IL-2 (PROJECT B7 (SLIT))

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 DESCRIPTION OF XXXX

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 DESCRIPTION OF XXXX

TABLE 21 DESCRIPTION OF XXXX

TABLE 22 DESCRIPTION OF XXXX

TABLE 23 DESCRIPTION OF VTC-064

TABLE 24 DESCRIPTION OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 ANAPTYSBIO INC.- AT A GLANCE

TABLE 27 AIMMUNE THERAPEUTICS INC. – AT A GLANCE

TABLE 28 COMPANY 3 – AT A GLANCE

TABLE 29 COMPANY 4 – AT A GLANCE

TABLE 30 COMPANY 5 – AT A GLANCE

TABLE 31 COMPANY 6 – AT A GLANCE

TABLE 32 COMPANY 7 – AT A GLANCE

TABLE 33 COMPANY 8 – AT A GLANCE

TABLE 34 COMPANY 9 – AT A GLANCE

TABLE 35 COMPANY 10 – AT A GLANCE

LIST OF FIGURES

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: PEANUT ALLERGY DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 5: PEANUT ALLERGY PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6: PEANUT ALLERGY PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9: KEY PLAYERS BENCHMARKING

FIG 10: SWOT ANALYSIS



★調査レポート[ピーナッツアレルギー治療薬市場:パイプライン分析・治験・特許・指定・協力・動向] (コード:PSM804034)販売に関する免責事項を必ずご確認ください。
★調査レポート[ピーナッツアレルギー治療薬市場:パイプライン分析・治験・特許・指定・協力・動向]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆